Lv4
450 积分 2022-11-07 加入
Atrasentan in Patients with IgA Nephropathy
10天前
已完结
Alternative Complement Pathway Inhibition with Iptacopan in IgA Nephropathy
10天前
已完结
Sparsentan in patients with IgA nephropathy: a prespecified interim analysis from a randomised, double-blind, active-controlled clinical trial
10天前
已完结
Efficacy and safety of a targeted-release formulation of budesonide in patients with primary IgA nephropathy (NefIgArd): 2-year results from a randomised phase 3 trial
10天前
已完结
Disitamab vedotin plus toripalimab in patients with locally advanced or metastatic urothelial carcinoma (RC48-C014): a phase 1b/2 dose-escalation and dose-expansion study
13天前
已完结
Ivonescimab versus pembrolizumab for PD-L1-positive non-small cell lung cancer (HARMONi-2): a randomised, double-blind, phase 3 study in China
27天前
已完结
Ivonescimab versus pembrolizumab for PD-L1-positive non-small cell lung cancer (HARMONi-2): a randomised, double-blind, phase 3 study in China
27天前
已完结
Tirzepatide as Compared with Semaglutide for the Treatment of Obesity
1个月前
已完结
Mepolizumab to Prevent Exacerbations of COPD with an Eosinophilic Phenotype
1个月前
已完结
GLP-1-based therapies for diabetes, obesity and beyond
1个月前
已完结
皖公网安备34019202002308
